[18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients

Pauwels, Elin; Celen, Sofie; Baete, Kristof; Bechter, Oliver; Bex, Marie; Renard, Marleen; Clément, Paul M.; Jentjens, Sander; Serdons, Kim; Laere, Koen Van; Bormans, Guy; Deroose, Christophe M.

doi:10.1007/s00259-022-06046-7

Cited by 8 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors calculated tracer incorporation in lesions at 1 and 2 h and also lesion detection rate on [ 18 F]-mFBG PET/CT with respect to that obtained with [ 123 I]-mIBG. In The biodistribution of [ 18 F]-mFBG resulted substantially similar to that reported in the 2 previously cited papers [8,9]. Notably, a decreasing trend in tracer incorporation was registered in normal organs between the PET scans carried out at 1 and 2 h, while tracer uptake in lesions remained substantially unchanged over time.…”

supporting

confidence: 83%

“…1) [11][12][13]. It is worth mentioning that, as reported in the previously cited papers [9,11], [ 18 F]-mFBG PET/CT significantly impacted on the calculation of SIOPEN score, providing a higher value than that calculated on [ 123 I]-mIBG scintigraphy. However, if and how much mFBG-based calculation might impact on the prognostic value of SIOPEN score in clinical practice is still unclear and will be topic of future investigations.…”

mentioning

confidence: 70%

“…A subsequent study carried out by Pauwels and collaborators assessed the biodistribution, safety and pharmacokinetics of [ 18 F]-mFBG in 6 NCT patients (PHEO/PGL = 5, NB = 1) and compared the diagnostic performance of [ 18 F]-mFBG PET/CT with respect to that of [ 123 I]-mIBG scintigraphy (whole body and SPECT/CT of an area of interest at about 24 h p.i.) [9]. Concerning the biodistribution study, the authors applied a substantially identical protocol with respect to the previously cited paper [8], reporting overlapping results.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Something old has become new: PET imaging of neural-crest tumors with [18F]-meta-fluorobenzylguanidine

Filippi

Schillaci

2023

Clin Transl Imaging

View full text Add to dashboard Cite

supporting

confidence: 83%

mentioning

confidence: 70%

mentioning

confidence: 99%

See 1 more Smart Citation

Something old has become new: PET imaging of neural-crest tumors with [18F]-meta-fluorobenzylguanidine

Filippi

Schillaci

2023

Clin Transl Imaging

View full text Add to dashboard Cite

“…New PET tracers that target NETs 124 I-MIBG can detect PCC with a high accuracy and can be used as a companion agent for selecting candidates for 131 I-MIBG ( 136 ). 18 F-meta-Fluorobenzylguanidine is also a promising alternative PET tracer to 123 I-MIBG ( 137 ). Beyond new tracers, nuclear medicine can also provide imaging biomarkers.…”

Section: Future Perspectivementioning

confidence: 99%

Imaging of Pheochromocytomas and Paragangliomas

Timmers,

Taïeb,

Pacak

et al. 2024

Endocrine Reviews

View full text Add to dashboard Cite

Pheochromocytomas/paragangliomas are unique in their highly variable molecular landscape driven by genetic alterations, either germline or somatic. These mutations translate into different clusters with distinct tumor locations, biochemical/metabolomic features, tumor cell characteristics (e.g. receptors, transporters) and disease course. Such tumor heterogeneity calls for different imaging strategies in order to provide proper diagnosis and follow-up. This also warrants selection of the most appropriate and locally available imaging modalities tailored to an individual patient based on consideration of many relevant factors including age, (anticipated) tumor location(s), size and multifocality, underlying genotype, biochemical phenotype, chance of metastases as well as the patient’s personal preference and treatment goals. Anatomical imaging using computed tomography and magnetic resonance imaging and functional imaging using positron emission tomography and single photon emission computed tomography are currently a cornerstone in the evaluation of patients with pheochromocytomas/paragangliomas. In modern nuclear medicine practice, a multitude of radionuclides with relevance to diagnostic work-up and treatment planning (theranostics) is available, including radiolabeled metaiodobenzylguanidine, fluorodeoxyglucose, fluorodihydroxyphenylalanine and somatostatin analogues. This review amalgamates up-to-date imaging guidelines, expert opinions as well as recent discoveries. Based on the rich toolbox for anatomical and functional imaging that is currently available, we aim to define a customized approach in patients with (suspected) pheochromocytomas/paragangliomas from a practical clinical perspective. We provide imaging algorithms for different starting points for initial diagnostic workup and course of the disease, including adrenal incidentaloma, established biochemical diagnosis, post-surgical follow-up, tumor screening in pathogenic variant carriers, staging and restaging of metastatic disease, theranostics and response monitoring.

show abstract

“…In addition, other PET tracers like [ 18 F]F-Fluorodopamine, [ 11 C]hydroxy-ephedrine and [ 11 C]epinephrine are currently undergoing clinical validation [69]. SSA PET tracers and other nuclear medicine techniques are used in certain cases, particularly when there are specific genetic mutations or tumor recurrence [70,71].…”

Section: Pet/ct In Adrenal Disordersmentioning

confidence: 99%

Endocrinology application of molecular imaging: current role of PET/CT

Calderoni,

Giovanella,

Fanti

2024

J Endocrinol Invest

View full text Add to dashboard Cite

Background In recent years, nuclear medicine imaging methods have proven to be of paramount importance in a wide variety of diseases, particularly in oncology, where they are crucial for assessing the extent of disease when conventional methods fall short. Moreover, nuclear imaging modalities are able to better characterize lesions using target agents related to specific pathways (e.g. glucose metabolism, cellular proliferation, amino acid transport, lipid metabolism, specific receptor ligands). The clinical presentation of endocrine diseases encompasses a broad spectrum of sign and symptoms. Moreover, endocrine tumors show varying degrees of aggressiveness from well differentiated and indolent to highly aggressive cancers, respectively. Rationale With the application of new medicinal radio-compounds and increasingly advanced tomographic imaging technology, the utility of Positron Emission Tomography/Computed Tomography (PET/CT) in the field of endocrine diseases is expanding. Aim This review aims to analyze and summarize the primary indications of PET/CT, providing a practical approach for clinicians. A comprehensive literature search on PubMed was conducted to provide an updated overview of the available evidence regarding the use of PET/CT in endocrinology. Within this review, we will discuss the applications of PET/CT, compare different radiopharmaceuticals and highlight the uptake mechanism, excluding neuroendocrine carcinomas from discussion. Conclusions PET/CT is a valuable tool in diagnosing and managing endocrine disorders due to its capacity to furnish both functional and anatomical information, facilitate early lesion detection, guide treatment decisions, and monitor treatment response. Its non-invasive nature and precision make it an integral component of modern endocrine healthcare. This review aims to provide physicians with a clear perspective on the role of PET/CT imaging, discussing its emerging opportunities and appropriateness of use in endocrinological diseases.

show abstract

[18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients

Cited by 8 publications

References 23 publications

Something old has become new: PET imaging of neural-crest tumors with [18F]-meta-fluorobenzylguanidine

Something old has become new: PET imaging of neural-crest tumors with [18F]-meta-fluorobenzylguanidine

Imaging of Pheochromocytomas and Paragangliomas

Endocrinology application of molecular imaging: current role of PET/CT

Contact Info

Product

Resources

About